Abstract
Spinal cord injury (SCI) is a devasting condition with no reliable treatment. Spina bifida is the most common cause of congenital SCI. Cell-based therapies using mesenchymal stem/stromal cells (MSCS) have been largely utilized in SCI. Several clinical trials for acquired SCI use adult tissue-derived MSC sources, including bone-marrow, adipose, and umbilical cord tissues. The first stem/stromal cell clinical trial for spina bifida is currently underway (NCT04652908). The trial uses early gestational placental-derived mesenchymal stem/stromal cells (PMSCs) during the fetal repair of myelomeningocele. PMSCs have been shown to exhibit unique neuroprotective, angiogenic, and antioxidant properties, all which are promising applications for SCI. This review will summarize the unique properties and current applications of PMSCs and discuss their therapeutic role for acquired SCI.
Highlights
Cell-based therapies for spinal cord injury (SCI) have been investigated in preclinical and clinical trials with limited success [1,2]
Cytokine arrays and single cell analysis have studied the secretome of placental early gestational chorionic villusderived mesenchymal stem/stromal cells (MSCs) (PMSCs), which is key to understanding the differences between various MSCs
Proteomic analysis of PMSC extracellular vesicles (EVs) revealed the presence of several proteins and RNAs involved in neuronal survival
Summary
Edwin S Kulubya 1,2 , Kaitlin Clark 1,3 , Dake Hao 1,3 , Sabrina Lazar 1,3 , Arash Ghaffari-Rafi 2 , Tejas Karnati 2 , Julius Okudu Ebinu 2 , Marike Zwienenberg 2 , Diana L Farmer 1,3 and Aijun Wang 1,3,4, *.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
